Pilot Study to evaluate glycemic variability measured by continuous glucose monitoring in high-risk individuals with normal hemoglobin A1c levels (HbA1c <5.7%)

Brief description of study

Screening for glucose disorders may underestimate the prevalence of dysglycemia in individuals with a normal HbA1c (< 5.7%) at high-risk for progression to type 2 diabetes (T2DM) [presence of one or more of the following: overweight, obesity, polycystic ovarian syndrome (PCOS), fatty liver (NAFLD), metabolic syndrome (MS), hypertension, primary family history of diabetes, or history of gestational diabetes (GDM)]. Subjects will undergo an oral glucose tolerance test (OGTT) and wear a subcutaneous continuous glucose monitoring (CGM) sensor for 14 days that can detect dysglycemia and glycemic variability (GV) which has been associated with vascular damage and mortality.

Clinical Study Identifier: s18-00140
Principal Investigator: Michael Bergman
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.